Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression

W. I. Gonsalves, S. V. Rajkumar, A. Dispenzieri, D. Dingli, M. M. Timm, W. G. Morice, M. Q. Lacy, F. K. Buadi, R. S. Go, N. Leung, P. Kapoor, S. R. Hayman, J. A. Lust, S. J. Russell, S. R. Zeldenrust, L. Hwa, T. V. Kourelis, R. A. Kyle, M. A. Gertz, S. K. Kumar

Research output: Contribution to journalArticlepeer-review

27 Scopus citations

Abstract

The presence of high numbers of circulating clonal plasma cells (cPCs) in patients with smoldering multiple myeloma (SMM), detected by a slide-based immunofluorescence assay, has been associated with a shorter time to progression (TTP) to MM. The significance of quantifying cPCs via multiparameter flow cytometry, a much more readily available diagnostic modality, in patients with SMM has not been evaluated. This study evaluated 100 patients with a known or new diagnosis of SMM who were seen at the Mayo Clinic, Rochester from January 2008 until December 2013. Patients with ≥150 cPCs (N=9) were considered to have high number of cPCs based on the 97% specificity and 78% PPV of progression to MM within 2 years of cPC assessment. The median TTP of patients with ≥150 cPCs was 9 months compared with not reached for patients with <150 cPCs (P<0.001). Thus, quantification of cPCs via multiparametric flow cytometry identifies patients with SMM at very high risk of progression to MM within 2 years and warrants confirmation in larger studies. In the future, this may allow reclassification of such patients as having MM requiring therapy prior to them enduring end-organ damage.

Original languageEnglish (US)
Pages (from-to)130-135
Number of pages6
JournalLeukemia
Volume31
Issue number1
DOIs
StatePublished - Jan 1 2017

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression'. Together they form a unique fingerprint.

Cite this